Congress has a clear shot at cutting U.S. drug costs

  • William Raspberry / Washington Post columnist
  • Thursday, September 28, 2000 9:00pm
  • Opinion

WASHINGTON — There are at least two pieces of the problem of the high cost of prescription drugs, Rep. Bernie Sanders, I-Vt., has been saying for some time now.

But most of the political and journalistic focus has been on only one piece: The "outrageously high price" both seniors and nonseniors alike have to pay for their medications. He’d like to call attention to the other half of the problem: The fact that Americans "are paying by far the highest prices in the world for the same exact drug — not a generic, but the same exact drug."

The solution, he says, is simplicity itself. Allow registered pharmacists and drug distributors to purchase FDA-approved drugs anywhere in the world for resale here. Re-importation, he calls it in the bill he hopes will pass Congress before the campaign recess.

That could be as early as Oct. 6.

"This is important stuff," Sanders said in a telephone interview from his Burlington office. "I traveled to Canada with a group of women with breast cancer, and we looked at the price of tamoxifen, a drug that is widely prescribed for the treatment of breast cancer. You could get it in Canada at a tenth of the U.S. price.

"If this bill were to go into effect tomorrow, U.S. pharmacies would be purchasing tamoxifen in Canada and retailing it here at 30 to 50 percent less than they now charge."

Sanders says the same thing applies in any number of countries with any number of drugs — all approved by the FDA and originally manufactured in or exported from the United States.

"Pharmacies should be able to purchase these drugs the same way other companies purchases shoes, slacks or washing machines," he says.

Is his proposal an attempt to derail legislation calling for a prescription drug benefit, at least for senior citizens? Both Democrats and Republicans seem determined to pass such legislation as a way of combating the high cost of medicine.

"There’s no conflict there," Sanders insists. "Even if we were able through my bill to lower the cost of prescription drugs 30 to 50 percent, we would still need the prescription drug benefit. I support that."

Indeed, he argues, his proposal, whose basic concept already has cleared both houses of Congress as part of an agricultural appropriations bill, would make the other legislation more effective. For example, a Democratic bill would require a Medicare beneficiary to pay $288 of the first $1,000 in prescription costs, and half of the next $1,000. Allowing re-importation would make it possible for Medicare to cover up to 80 percent of prescription costs "just because, with lowered costs, there’d be more money to go around."

So who could oppose such a simple notion?

Some early opposition was based on fear that unsafe or bogus drugs would be brought into the States. The Pharmaceutical Research and Manufacturers of America (PhRMA) has run ads warning that re-importation would "result in adulterated, spoiled and counterfeit drugs in America’s medicine cabinets."

But former FDA commissioner David A. Kessler, who earlier opposed re-importation for just that reason, said recently he’s been satisfied that limiting re-importation to drugs already approved by the FDA and manufactured in FDA-approved facilities would eliminate that hazard. Sanders says batch testing of the re-imports should cost between $800 and $3,000 per batch, an "insignificant" additional cost to batches of drugs "worth hundreds of thousands to millions each."

The biggest obstacle to passage this term is the pharmaceutical industry, Sanders says. "They are the most powerful lobbying force on Capitol Hill," he said. "They’ve spent tens of millions in opposition of this bill. They have 300 paid lobbyists and funneled $6 million to the Republicans and $3 million to the Democrats. That’s $9 million in political contributions we’re going up against."

And his best hope for passage? "This is the issue that is of the most concern to the people and to members of Congress. Both parties want to go home saying we did something about the high cost of prescriptions."

Talk to us

More in Opinion

Editorial cartoons for Wednesday, Feb. 8

A sketchy look at the news of the day.… Continue reading

The Snohomish County Auditor's Office is one of many locations where primary election ballots can be dropped off on Tuesday. (Sue Misao / The Herald) 20180806
Editorial: Voting’s a duty, but should it be mandatory?

Legislation to require voter registration and voting needs more discussion among the public, first.

Back bill to allow more accessory dwelling units in neighborhoods

We are all well aware of the unaffordable housing costs for many… Continue reading

Strong schools imporant to city; vote yes on Marysville levy

As a concerned parent of three and citizen of Marysville, I ask… Continue reading

What about the Herald carriers who lost their jobs?

In all the pros and cons about The Herald’s switch to U.S.… Continue reading

Comment: When robots come for your job, they’ll fire you first

AI is taking the human out of human resources by evaluating performance and recommending whom to cut.

Comment: It’s not federal debt’s $’s but %’s we should worry about

Focus on our ability to pay off debt through a balanced budget. The percentages are concerning.

Herald columnist Julie Muhlstein received this card, by mail at her Everett home, from the Texas-based neo-Nazi organization Patriot Front.  The mail came in June, a month after Muhlstein wrote about the group's fliers being posted at Everett Community College and in her neighborhood.  (Dan Bates / The Herald)

(Dan Bates / The Herald)
Editorial: Treat violent extremism as the disease it is

The state Attorney General urges a commission to study a public health response to domestic terrorism.

Photo Courtesy The Boeing Co.
On September 30, 1968, the first 747-100 rolled out of Boeing's Everett factory.
Editorial: What Boeing workers built beyond the 747

More than 50 years of building jets leaves an economic and cultural legacy for the city and county.

Most Read